The pharmaceutical company “ChemRar” expands its production capacity, investing more than 1 billion rubles in the construction of a new plant for the production of pharmaceutical substances. This is reported by the press-service of Glavgosstroynadzor of Moscow region.

The report notes that with the support of the Center for Construction Assistance, the manufacturer of innovative pharmaceuticals, is expanding its production capacity through the construction of a new high-tech complex, which will include the production of active pharmaceutical substances, storage facilities, as well as a workshop for the development of intermediates for AFS. The new production line of API-Technologies will increase the capacity of the developer – ChemRar Group of Companies – more than five times. The total investment in the project will amount to more than 1 billion rubles.

The project is being realized with the support of the Industrial Development Fund, the Ministry of Industry and Trade of the Russian Federation, and the Government of the Moscow Region. The construction permit for the facility was issued by Glavgosstroynadzor of the Moscow Region.

The production complex will be located in the Khimki urban district on the territory of the ChemRar High Technology Center, which already performs a full cycle of research, development and production of both import-substituting and innovative new-generation drugs for the treatment of diseases of the central nervous system, oncology, HIV infection, as well as influenza, coronavirus, etc.

It is planned that the new production site will produce substances for innovative drugs from the company’s current portfolio of products against HIV infection and for the treatment of anxiety disorders, including those arising after coronavirus infection.

Construction is expected to be fully completed by the end of 2024, with full production start-up scheduled for Q1-Q2 2025.